Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Diferenciālā metabolomikas analīze× | RNA-seq diferenciālās ekspresijas× | |
|---|---|---|
| Nozare | Bioinformātika | Bioinformātika |
| Saime | Process / pipeline | Process / pipeline |
| Izcelsmes gads≠ | 2000s–2010s (field formalised alongside mass spectrometry advances) | 2008–2010 (RNA-seq DE methodology established) |
| Autors≠ | Developed through convergent contributions by multiple groups; XCMS (Siuzdak lab, 2006) and MetaboAnalyst (Wishart lab, 2009–2015) are foundational computational implementations | Multiple groups; foundational methods from Anders & Huber (DESeq, 2010), Robinson, McCarthy & Smyth (edgeR, 2010) |
| Tips≠ | Quantitative comparative omics pipeline | Quantitative genomics pipeline |
| Pirmavots≠ | Xia, J., Sinelnikov, I. V., Han, B., & Wishart, D. S. (2015). MetaboAnalyst 3.0 — making metabolomics more meaningful. Nucleic Acids Research, 43(W1), W251–W257. link ↗ | Love, M. I., Huber, W., & Anders, S. (2014). Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology, 15(12), 550. DOI ↗ |
| Citi nosaukumi | comparative metabolomics, differential metabolite profiling, metabolomic differential analysis, DMA | RNA-seq DE analysis, transcriptomic differential expression, bulk RNA-seq DE, DEA |
| Saistītās | 6 | 6 |
| Kopsavilkums≠ | Differential metabolomics analysis is a computational pipeline that identifies metabolites whose abundance levels differ significantly between two or more biological conditions — such as disease versus control, treated versus untreated, or different developmental stages. By integrating mass spectrometry or NMR data with statistical modelling and pathway databases, it translates raw spectral measurements into biologically interpretable lists of perturbed metabolic features and the pathways they implicate. | RNA-seq differential expression (DE) analysis identifies genes whose transcript abundance differs significantly between two or more biological conditions — for example, treated versus control, or diseased versus healthy tissue. Starting from raw sequencing reads, the pipeline moves through alignment, count-based normalization, statistical modeling of count dispersion, hypothesis testing, and multiple-testing correction to produce a ranked list of differentially expressed genes accompanied by fold-change estimates and adjusted p-values. |
| ScholarGateDatu kopa ↗ |
|
|